Three Top CRISPR Stocks to Own in 2023

January 25, 2023 www.tradewins.com Other Exciting News Unleash the Power of Profitable Trading at FFR Trading's Roundtable 2023 Join renowned traders Lee Gettess and Joe Duffy as they take an in-depth look at the past trading year and give you an exclusive glimpse into the future. Don't miss out on this opportunity to gain valuable insights and strategies to take your trading game to the next level. Mark your calendars for an event you won't want to miss! Thursday, January 26th at 4:30pm EST / 3:30pm CST / 1:30pm PST Register Here Attention all traders! Get ready for an electrifying experience as FFR Trading and Trader's Edge invite you to our highly-anticipated annual Roundtable 2023 event! An incredible bonus offer from both Lee Gettess and Joe Duffy will be offered to all subscribers who stay for the entire webinar. The eBooks will help you propel your 2023 trading year! Register Now Recent Articles Three Top CRISPR Stocks to Own in 2023 by Ian Cooper Three Strategies for Forex Traders by Ellie Taft Guaranteed Real Optioneering Winners by Chuck Hughes TradeWins Author Team     Tomorrow, you could begin doubling your account every single month starting with one letter. The letter will come from a 20-year trading professional named Ian Cooper. He says, “In 2022, following my trades you would be doubling even tripling your account some months. Let me show you how.” He will show you exactly what to do... and he’ll give you the blueprint for just $1. Get Daily Trade Alert Now About TradeWins Inside Trading Newsletter Webinars Videos Trading Strategy Options Futures Forex Day Trading Subscription Services E-Books Customer Satisfaction Survey 2020 Three Top CRISPR Stocks to Own in 2023 by Ian Cooper CRISPR could revolutionize our health. At the moment, there are about 7,000 caused by genetic disorders, which occur when a mutation affects your genes, or when you have the wrong amount of genetic material, as noted by the Cleveland Clinic. Fortunately, CRISPR, or clustered regularly interspaced short palindromic repeats, has the potential to treat all of them. CRISPR Therapeutics (CRSP) There’s big news ahead for CRISPR Therapeutics (CRSP). Along with Vertex Pharmaceuticals (VRTX), the company’s exagamglogene autotemcel (exa-cel) could see approval for the treatment of sickle cell disease and transfusion dependent beta thalassemia (TDT) shortly. At the moment, the companies are preparing to submit a Biologics License Applications (BLA) for the treatment at the close of the first quarter. Global X Genomics and Biotechnology ETF (GNOM) Or, if you want to diversify at less cost, consider an ETF, such as the Global X Genomics and Biotechnology ETF (GNOM). At $13.65 with an expense ratio of 0.50%, the ETF offers exposure to advances in n gene editing, genomic sequencing, genetic medicine/therapy, computational genomics, and biotechnology. Even better, the GNOM ETF offers exposure to 40 stocks, including Intellia Therapeutics, CRISPR Therapeutics, Myriad Genetics, Sarepta Therapeutics, Gilead Sciences, Editas Medicine, and Sangamo Therapeutics to name a few. Read More   Three Strategies for Forex Traders by Ellie Taft Strategy #1: Jump the Gun “Jump the Gun” is a very simple concept based on fundamentals. But, for successful execution you must be out of the box before everyone else! Here’s how it works… First, set yourself up with an up-to-the-second news feed that gets the numbers to you before they’re announced on Bloomberg and Reuters. Premium news feeds can cost as much as $2,000 a month. But I know of a couple under $100 that should suffice. Then, pick a high-impact report from the economic calendar and note the forecasted number. Consider how a deviation from the forecast would impact the homeland currency. And formulate your strategy. For example, on February 8th the Canadian Labor Change report was due out at 7:00am ET. Forecast: 10,000 jobs. If substantially more than 10,000 new jobs have been created, that would be good for the Canadian Dollar… meaning USD/CAD and EUR/CAD should spike down. A number considerably lower than 10,000 would cause a spike up. Read More Guaranteed Real Optioneering Winners by Chuck Hughes The first profit opportunity we will review this week is a stock purchase in EXTR, or Extreme Networks, Inc. This company provides a next generation of switching solutions for enterprise local area networks ISPs and content providers. The monthly chart shows that EXTR has been in an overall bull trend since 2020. The recent pause gives us a buying opportunity. The daily chart shows that EXTR has a bullish pattern of higher highs and higher lows. The bullish pattern points to a further advance. We recommend buying EXTR stock at current price levels. Read More   www.tradewins.com                © Copyright 2023 TradeWins.com. All rights reserved. TradeWins Publishing, 22C New Leicester Hwy, #117, Asheville, NC 28806 Email: support@iss-trading.com   |   Phone: 888-233-1431   |   Fax: 888-258-4938   PLEASE READ: Auto-trading, or any broker or advisor-directed type of trading, is not supported or endorsed by TradeWins. For additional information on auto-trading, you may visit the SEC’s website: All About Auto-Trading, TradeWins does not recommend or refer subscribers to broker-dealers. You should perform your own due diligence with respect to satisfactory broker-dealers and whether to open a brokerage account. You should always consult with your own professional advisers regarding equities and options on equities trading. 1) The information provided by the newsletters, trading, training and educational products related to various markets (collectively referred to as the “Services”) is not customized or personalized to any particular risk profile or tolerance. Nor is the information published by TradeWins Publishing (“TradeWins”) a customized or personalized recommendation to buy, sell, hold, or invest in particular financial products. The Services are intended to supplement your own research and analysis. 2) TradeWins’ Services are not a solicitation or offer to buy or sell any financial products, and the Services are not intended to provide money management advice or services. 3) Past performance is not necessarily indicative of future results. Trading and investing involve substantial risk. Trading on margin carries a high level of risk, and may not be suitable for all investors. Other than the refund policy detailed elsewhere, TradeWins does not make any guarantee or other promise as to any results that may be obtained from using the Services. No person subscribing for the Services (“Subscriber”) should make any investment decision without first consulting his or her own personal financial adviser, broker or consultant. TradeWins disclaims any and all liability in the event anything contained in the Services proves to be inaccurate, incomplete or unreliable, or results in any investment or other loss by a Subscriber. 4) You should trade or invest only “risk capital” – money you can afford to lose. Trading stocks and stock options involves high risk and you can lose the entire principal amount invested or more. 5) All investments carry risk and all trading decisions made by a person remain the responsibility of that person. There is no guarantee that systems, indicators, or trading signals will result in profits or that they will not produce losses. Subscribers should fully understand all risks associated with any kind of trading or investing before engaging in such activities. 6) Some profit examples are based on hypothetical or simulated trading. This means the trades are not actual trades and instead are hypothetical trades based on real market prices at the time the recommendation is disseminated. No actual money is invested, nor are any trades executed. Hypothetical or simulated performance is not necessarily indicative of future results. Hypothetical performance results have many inherent limitations, some of which are described below. Also, the hypothetical results do not include the costs of subscriptions, commissions, or other fees. Because the trades underlying these examples have not actually been executed, the results may understate or overstate the impact of certain market factors, such as lack of liquidity. Simulated trading services in general are also designed with the benefit of hindsight, which may not be relevant to actual trading. In addition, hypothetical trading does not involve financial risk, and no hypothetical trading record can completely account for the impact of financial risk of actual trading. TradeWins makes no representations or warranties that any account will or is likely to achieve profits similar to those shown. 7) No representation is being made that you will achieve profits or the same results as any person providing testimonial. No representation is being made that any person providing a testimonial is likely to continue to experience profitable trading after the date on which the testimonial was provided, and in fact the person providing the testimonial may have experienced losses. 8) The author experiences are not typical. The author is an experienced investor and your results will vary depending on risk tolerance, amount of risk capital utilized, size of trading position and other factors. Certain Subscribers may modify the author methods, or modify or ignore the rules or risk parameters, and any such actions are taken entirely at the Subscriber’s own election and for the Subscriber’s own risk.

If you wish to stop receiving our emails or change your subscription options, please Manage Your Subscription
TradeWins Publishing, 528 North Country Rd., St. James, NY 11780

Share on Facebook

Share on Twitter

Share on Google+

Share on LinkedIn

Subscribe to receive free email updates: